In the context of the explosion of software artificial intelligence, its influence on each field is huge, but it will be different. Today we will talk about the impact of artificial intelligence technology on medicine. What the experts said.

This year, AlphaGo Zero came out, learning from the human map to learn from humans, about the impact of artificial intelligence technology on Chinese medicine, on December 2nd, at the second China Medical Entrepreneur Conference held in Hangzhou. The proposition was discussed.

Artificial intelligence has been at the forefront of the past two years, mainly in 2016 AlphaGo defeated world champion Li Shishi as a landmark event, artificial intelligence technology began to accelerate on each track. This year, AlphaGo Zero came out, learning from the human map to learn from humans, about the impact of artificial intelligence technology on Chinese medicine, on December 2nd, at the second China Medical Entrepreneur Conference held in Hangzhou. The proposition was discussed.

In the past two years, artificial intelligence has become a craze. Qian Jianzhong, founder and chairman of EDDA Technologies, said that the reasons for the artificial intelligence technology in the past two years were mainly affected by big data and digital. In addition, Liao Jieyuan, founder and chairman of Micromedical, used data and policy as two preconditions.

"There is no data, no blood, no IQ." Liao Jieyuan believes that the premise of data is connectivity. But at the same time, he also mentioned that when artificial intelligence is combined with medical treatment, if the data does not reach integrity, it means an increase in risk. How to make artificial intelligence based on complete data will be a question worth considering.

In response to the combination of AlphaGo Zero and the medical field and Liao Jieyuan's thinking, Liu Wei, CEO of Huada Gene Innovation Center, divides the data into two dimensions: full data and brain-like intelligence. This is related to Shulan Medical Management Group. President Zheng Jie's view of dividing artificial intelligence into artificial intelligence and virtual people is very different.

In the first dimension, AI is mainly developed from the expert database to deep learning in collaboration with data scientists and doctors. AI may be able to summarize and summarize all data, and it needs to be derived from the most basic principles, but Liu Wei believes that induction is Unreliable. In the second dimension, the role of AI in the field of virtual humans is explored mainly from the perspective of artificial life. In the words of Liu Wei, it is called brain-like intelligence. Life-related possible medicinal drugs are pushed with great care and caution. Liu Wei said that it is not particularly agreeable that artificial intelligence can replace many and many things now. It should be steadily advanced because there are many kinds of technological evolution.

At the same time, Zheng Jie also said that it is still too early to talk about the application of AlphaGo Zero in the medical field. But the basis of artificial intelligence is big data. Facing the current AI vents, identifying real artificial intelligence companies also needs data as a reference.

"Big data is not equal to good data. Good data does not mean useful medical information." Qian Jianzhong said that although artificial intelligence based on big data shows various benefits in the field of medicine, the fragmentation and incompleteness of data make it The data lacks formatting and standardity. Therefore, he believes that turning big data into useful good data and applying it to products is still very challenging.

While identifying artificial intelligence companies, Qian Jianzhong also said that the data should be dynamic and focus on clinical data. This is consistent with Liao Jieyuan's view that data should be connected. Through the connection of offline data, the data of the fragments will be integrated into a flowing data. Combined with doctors and hospitals, the utility of data can really be realized.

Liao Jieyuan believes that the scene belongs to derived living data, dynamic structured data, accounting for nearly 30% of the component, and the evolution of technology accounts for 10%. In addition, he believes that the premise of data sharing is policy.

Zhu Xun, an expert from the National New Drug Evaluation Committee, said that in the field of medicine, China has adopted pre-approval and government control measures. He believes that in China's pharmaceutical field, China's creation is based on Chinese consumption.

In this regard, he believes that medicines need to guarantee three points:

The first is that if it is a French pharmaceutical, it must be of high quality and low cost. The two are inherently contradictory. However, China is a big country, but generic drugs must be consistent with the original drug. Originally, China did not introduce this policy. Now it is making up the class. Consistency is to let the people use high-quality and low-cost drugs instead of Cottage medicine

The second is the availability of the latest, high-quality drugs and the availability of prices to a certain extent. In the current China, in this regard, due to the previous three reports and three batches of policies, this change including the inclusion of ICH has enabled the Chinese people to quickly access the latest, safest and most reliable drugs in the world. Acquired;

The third is inadequate, and insufficient means that people's rigid needs are not met.

At present, although in the medical field, companies and funds have joined the track, but Tencent, Ping An, Baidu and other giants have begun to layout. Mentioning the development of domestic pharmaceutical companies in the future artificial intelligence pattern, and the possibility of oligopoly may occur in the future medical field, and the speeches of the Secretary General of the Freehand Forum, Cheng Zengjiang and the founder of the Unicorn Studio, Liu Qian are worried.

Although Wu Xiaobin and Liao Jieyuan, presidents of Pfizer Greater China, have mentioned that small businesses still have a lot of room to rise in the future, seize the blue ocean and cooperate with large enterprises. However, in the current situation of the pharmaceutical industry in the Red Sea, how domestic pharmaceutical companies seize the opportunity to take advantage of the road to develop national enterprises, Cheng Zengjiang still expressed concern at the end.

In this regard, Zhu Xun believes that generic drugs will be the first step in the future development of domestic pharmaceutical companies.

Unitech Barcode Scanner Battery

Unitech Battery,Unitech Scanner Batteries,Unitech Barcode Scanner Battery,Unitech Norand Symbol Barcode Scanner Battery

Shenzhen Sunwind Energy Tech Co.,Ltd , https://www.sunwindbatterylm.com